Last Updated: 04/06/07
CTEP Significant Ongoing Clinical Trials
- A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma
- A Phase IIb Study of Molecular Responses to Imatinib, at Standard or Increased Doses, or Dasatinib for Previously Untreated Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase
- Phase II Pilot Trial of Sorafenib Plus Interferon Alpha-2b in Metastatic Renal Cell Cancer
- Targeted Therapy Combinations in Glioma, Melanoma, and Renal Cell Cancer
